RecruitingPhase 4NCT07448844

Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir

Sponsor

Riphah International University

Enrollment

40 participants

Start Date

Feb 20, 2026

Study Type

INTERVENTIONAL

Conditions

Common Wart Flat Wart Plantar Wart Viral Wart Common Warts (Verruca Vulgaris)Warts of Foot Warts Hand Wart

Summary

The goal of this clinical trial is to learn if injecting acyclovir (an antiviral drug) or vitamin D3 directly into skin warts works to clear them in people aged 12 and older with common, plantar, flat, or periungual (around the nail) warts. The main questions it aims to answer are: 1. Does intralesional acyclovir or vitamin D3 lead to complete clearance of warts by week 8? 2. Which treatment clears warts more effectively? 3. What side effects do participants have with each treatment? Researchers will compare acyclovir injections (Group A) to vitamin D3 injections (Group B), with 20 participants in each group, to see which treatment works better at clearing warts. Participants will: 1. Receive an injection directly into the wart every 2 weeks for up to 4 sessions 2. Have photographs taken of their warts before treatment and at each visit 3. Visit the clinic for checkups where the size and number of warts will be measured 4. Be followed for up to 3 months to check for wart recurrence and side effects

Eligibility

Min Age: 12 Years

Inclusion Criteria3

Patients aged 12 years and above with clinically diagnosed cutaneous warts
Common, plantar, flat, or periungual warts
Both treatment-naïve patients and those with recalcitrant warts

Exclusion Criteria6

Pregnant or lactating women
Immunocompromised patients
Individuals with history of hypersensitivity to vitamin D3 or acyclovir
Individuals receiving systemic immunosuppressive or antiviral therapy
Patients with secondary infection at injection site
Patients who had received any topical or destructive treatment for wart in previous three months

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIntralesional Acyclovir

Acyclovir (70 mg/mL) prepared by reconstituting a 250 mg vial with 3.5 mL of distilled water, injected directly into the wart lesion. Dosing is based on lesion size: 0.2 mL for warts ≤0.5 cm, 0.3-0.5 mL for 0.5-1 cm, and 0.5-1 mL for 1-1.5 cm. Administered at baseline and every 2 weeks for up to four sessions.

DRUGIntralesional Vitamin D3

Vitamin D3 (200,000 IU; 5 mg/mL) injected directly into the wart lesion. Dosing is based on lesion size: 0.2 mL for warts ≤0.5 cm, 0.3-0.5 mL for 0.5-1 cm, and 0.5-1 mL for 1-1.5 cm. Administered at baseline and every 2 weeks for up to four sessions.